DTCA Case Studies

Despite this, the industry did not alter its ways, maintaining that its ad campaigns were "educational," and that people were able to make their own decisions about what they purchased (Payer 66). However, it is evident that the advertisements produced by the pharmaceutical industry are designed for the very purpose of making it difficult for people to make these decisions independently. This marketing produces a large number of often deceptive, misleading tactics which have a large influence on both consumers and medical practitioners. The chief beneficiaries of this marketing are not the consumers but the pharmaceutical companies themselves.

The purpose of this paper is to address the state of prescription drugs within today’s society, as it relates to areas of development, approval, cost, and competition. There will be look at the benefits, such as continued research may lead to the development of new breakthrough prescription drugs. On the opposite end, there is an in-depth look at the controversies that surround the prescription drug industry. These include the many, often severe side effects that accompany many of these drugs, and how they are allowed to make it past FDA approval, as well as, a look at the rising cost of prescription drugs. Tied with the increasing cost, is a comparative look at the similarities and differences of brand name drugs versus their

Patient actively engagement in their health care decision- making is definitely one part of achieving the National Quality Strategic plan and this

But have we reached the point in time where the treatment has become somewhat of an overkill? It can be argued that today, advertising for psychiatric medication has gotten out of hand, pushing out newer drugs that appeal to every little problem people seem to complain about these days. “Is psychiatry for sale?: An examination of the influence of the pharmaceutical industry on academic and practical psychiatry” Is a Maudsley Discussion paper, a series of short papers that deal with controversial issues in mental health. This discussion paper is written by Joanna Moncrieff, a British psychiatrist and part of the Critical Psychiatry Network. She primarily analyzes the influence of the pharmaceutical industry in the psychiatric field. Even though the paper is over ten years old, it provides insight into what is still most likely happening. She argues that because the industry is heavily involved in funding psychiatric research, that psychiatric practices could be directed by a profit-focused agenda (Moncrieff). She suggests that excessive advertising and research findings are likely produced to benefit this agenda, and likely causes the fabrication of specific disorders to create markets for new medications. It can be assumed that such an operation is capable of produce some widely dangerous outcomes, even if it is a small percent of the

There are many direct to consumer advertising for prescription drugs. On television, magazines, radio etc, you see the most recent advertisements for prescription drugs. After some people see the advertisements they soon rush over to their doctor and their illness and life would be perfectly pain and stress free. Making the public conscious of options for treatment is not a bad thing. But these false advertisements are misleading consumers onto unnecessary treatment.

There are existing FDA regulatory standards about truthful drug advertising and promotion. It is FDA's mission to ensure the enforcement of better communication of labeling and promotional information. The mere inclusion of disease information in promotional materials is discouraged as it is misleading. Based on a study conducted by FDA, they found out that exposure to disease information as part of DTC prescription drug ad leads people to believe that a drug treats or addresses all the conditions mentioned in the disease

If a house is on a fault –line, it would be difficult to find a buyer for such a house.

Differentiated thyroid carcinoma (DTC) is the most common cancer of the endocrine system. The survival rate of patients diagnosed with DTC is around 90%. The disease primarily affects young patients. The most common treatment for DTC is thyroid removal, followed by ablation of the remaining tissue with radioactive iodine (RAI) therapy. One concern for these patients is the risk of developing a nonsynchronous second primary malignancy (NSPM) during their lifetime. There have been previous studies that have concluded that approximately 30% to 40% of DTC survivors have a higher risk for developing a NSPM. The article “Risk of secondary primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy” compares

Has the patient been informed of benefits and risks, understood this information, and given consent?

Hi Eric, please find the DTC’s along with the test execution screenshots, on the requirement “ServiceOn 14B northbound Ericsson MiniLink TN 5.3 network element performance data.” I consulted with the test team member on it and no testing was carried on “ServiceOn 14B northbound Ericsson MiniLink TN 5.3 network element performance

Facts that emphasize dTTP's role in stabilizing the activated ACNase are that dTTP was showed to be crucial for stabilization of the core ACNase activity of free PrrC ( Blanga-Kanfi et al., 2006)as Isolated EcoPrrC has overt ACNase activity refractory to Stp and GTP but unstable without dTTP or a non-hydrolyzable dTTP analogue( Morad et al., 1993;Amitsur et al., 2003;Blanga-Kanfi et al., 2006).Likewise, the dramatic increase in dTTP's level during phage T4 infection was shown important for the ACNase activity of the activated PrrC (Meidler et al,.1999) and it may be required only for stabilizing the activated form. Moreover, dTTP binding was suggested to stimulate the activation, by triggering GTP utilization by its binding (Amitsur et al., 2003) and for the increase in the cellular level of dTTP before the onset of T4 DNA replication and ACNase activation (Blanga-Kanfi et al., 2006).

Arnetz, Zhdanova, and Arnetz (2016) report that better health outcomes and higher patient satisfaction are some advantages of patient involvement in medical treatment. Ac-tive participation in clinical decisions entails modifications on health care approach, re-specting personal preferences, which can result in delaying progression of the disease, pro-longing patient quality of life and effective health management. Similarly, current research is focused on promoting the value of a patient centered approach. Respecting patient’s deci-sions and preferences, has been linked to better adherence to medical regimen and better self-care management of the disease. It suggests that patient’s understanding will have posi-tive effect on the treatment

Finally, Guadagnoli and Ward (1998) observed that patients needed to be very much informed; however, they preferred decisions to be made by their doctors. Beisecker and Beisecker (1990), gained matching results when they asked patients about the need for medication and which dose of a medication should be taken; most of the interviewed patients said they liked to leave the responsibility for decision-making in the hands of their

Physicians can empower the patient by telling truth before any invasive procedure. In addition to that the outcome of any medical condition can be explained deeply to prevent future misunderstanding. “The pervasive uncertainty in medicine can and should be shared with patients. Telling patients about the clinical uncertainties and the range of options available to them allows them to appreciate the complexities of medicine, to ask questions, to make informed, realistic decisions and to assume responsibility for those decisions”( (Herbert, Hoffmaster, Glass, &Singer, 1997, p. 226).

Foundation of CRM in the pharmaceutical industry is based on the prescribers (i.e. doctor) and sales force relationship. Pharmaceutical firms spend a large amount of money on marketing communication directed towards physicians. For example, the firm spent $ 8.5 billion on marketing communication( Padhy & Patnaik, 2008) directed at physicians (Wittink, 2002, Neslin, 2001) in the year 2000. Out of the above expenditure, the major head was under the detailing budget that included personal sales calls on physicians. Since detailing is a personal interaction between a physician and the firms representatives, the budget allocated are spent at the individual physician level for generating Long-term prescriptions for patients (Morelli and Konigsberg, 1992). Researchers (Narayanan, Manchand and Chintagunta, 2005) have also argued that such marketing efforts made by the firms may have both informative (e.g. reducing cognitive uncertainty) and a persuasive (e.g. inducing positive affect roles). The most